Press Releases

Press Releases

December 6, 2019
CytomX Therapeutics Announces New Employment Inducement Grants
SOUTH SAN FRANCISCO, Calif. , Dec. 06, 2019 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (NASDAQ:CTMX), a clinical-stage oncology-focused biopharmaceutical company pioneering a novel class of investigational antibody therapeutics based on its Probody™ therapeutic technology platform, today
Additional Formats
November 11, 2019
CytomX Therapeutics to Present at Upcoming Healthcare Conferences
SOUTH SAN FRANCISCO, Calif. , Nov. 11, 2019 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a clinical-stage oncology-focused biopharmaceutical company pioneering a novel class of investigational antibody therapeutics based on its Probody™ therapeutic technology platform, announced
Additional Formats
October 29, 2019
CytomX Therapeutics Announces Initiation of Phase 2 Clinical Trial Evaluating the Anti-PD-L1 Probody CX-072 in Combination with YERVOY® in Patients with Relapsed or Refractory Melanoma
- Updates Phase 1 PROCLAIM-CX-072-001 Ipilimumab Combination Study Data - SOUTH SAN FRANCISCO, Calif. , Oct. 29, 2019 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a clinical-stage oncology-focused biopharmaceutical company pioneering a novel class of investigational antibody
Additional Formats
October 24, 2019
CytomX Therapeutics to Announce Third Quarter 2019 Financial Results
Teleconference Scheduled for November 7, 2019, at 5:00 p.m. ET SOUTH SAN FRANCISCO, Calif. , Oct. 24, 2019 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a clinical-stage oncology-focused biopharmaceutical company pioneering a novel class of investigational antibody therapeutics
Additional Formats
October 18, 2019
CytomX Therapeutics Announces New Employment Inducement Grants
SOUTH SAN FRANCISCO, Calif. , Oct. 18, 2019 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (NASDAQ:CTMX), a clinical-stage oncology-focused biopharmaceutical company pioneering a novel class of investigational antibody therapeutics based on its Probody™ therapeutic technology platform, today
Additional Formats
August 28, 2019
CytomX Therapeutics to Present at Upcoming Healthcare Conferences
SOUTH SAN FRANCISCO, Calif. , Aug. 28, 2019 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a clinical-stage oncology-focused biopharmaceutical company pioneering a novel class of investigational antibody therapeutics based on its Probody™ therapeutic technology platform, announced
Additional Formats
Displaying 1 - 10 of 29